Skip to content

Science
Pipeline
Team
Publications
Press Releases
Contact

Contact us

Interested in learning more?

Explore the science
View publications

Name (required)

Please enter your name.

Email (required)

Please enter a valid email address.

Organization

Inquiry type

Message (required)

Please enter a message.

Leave this field empty

Thank you. Your message has been sent and our team will be in touch.

APX3330: A clinical-stage, first-in-class, oral small molecule targeting Inflammatory Bowel Disease through upstream modulation.

Company

Home
Science
Pipeline
Team

Resources

Publications
Press Releases

Contact

Contact us

APX3330 is an investigational compound and has not been approved by any regulatory authority.

© 2026 Apexian Pharmaceuticals. All rights reserved.